First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories
Study Details
Study Description
Brief Summary
This is a Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Safety, Tolerability and PK Profiles of Single and Multiple Ascending Doses of Antimicrobial Peptide PL-18 Vaginal Suppositories.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Antimicrobial Peptide PL-18 Vaginal Suppositories Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories |
Drug: Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Escalating doses of 1 mg (0.1%)、2.5mg (0.25%)、5 mg (0.5%)、10mg (1%)、15 mg (1.5%)；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
|
| Placebo Comparator: Placebo dose Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories |
Drug: Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
Dose 1、2、3、4 and 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories respective placebos；single dose administration；topical vaginal suppository ；multiple-dose administration after single dose administration a 3-day wash out period ; once-daily for 6 consecutive days;
|
Outcome Measures
Primary Outcome Measures
- Characterize safety profile of Antimicrobial Peptide PL-18 Vaginal Suppositories about the incidence of treatment emergent adverse events [38 days]
All AEs will be summarized by system organ class (SOC) and preferred term (PT). The numbers and percentages of subjects experiencing AEs will be calculated.
- The numbers and percentages of subjects experiencing vital sign abnormalities with/without clinical significance. [17 days]
Vital signs abnormalities will be summarized with descriptive statistics. Vital signs include body temperature, blood pressure, heart rate/pulse, respiration. Changes from the baseline of each test over time will be summarized.
- The numbers and percentages of subjects experiencing physical examination abnormalities with/without clinical significance. [Day 4 , Day 11 , Day 17]
Physical examinations abnormalities will be summarized with descriptive statistics. Physical examination will include general condition, skin, head, eyes, ears, nose, throat, heart, lungs, chests, abdomen, extremities, nerves, back/spine, lymph, nodes. Changes from the baseline of each test over time will be summarized.
- Safety assessment about the changes of clinical laboratory tests. [Day2, Day 4 , Day5, Day 8, Day 11 , Day 17]
Laboratory abnormalities will be summarized with descriptive statistics. Clinical laboratory tests include hematology, blood chemistry, level of immune factors, urinalysis.
- Safety assessment about the changes of 12-lead ECG . [Day1, Day 4 , Day 5, Day 7, Day 11 , Day 17]
12-lead ECG abnormalities will be summarized with descriptive statistics.
Secondary Outcome Measures
- Maximum plasma concentration (Cmax) [Day1~Day4]
Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured.Maximum plasma concentration (Cmax) is a PK parameter of the single-dose stage.Plasma concentrations at different time points will be listed and summarized by descriptive statistics.
- Time to Maximum plasma concentration (Tmax) [Day1~Day4]
Tmax is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t) [Day1~Day4]
AUC0-t is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Area under concentration-time from time zero to infinity (AUC0-inf) [Day1~Day4]
AUC0-t is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Terminal half-life (t1/2) [Day1~Day4]
t1/2 is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Apparent clearance (CL/F) [Day1~Day4]
CL/F is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Apparent volume of distribution (Vz/F) [Day1~Day4]
Vz/F is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Mean residence time (MRT) [Day1~Day4]
MRT is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Terminal elimination rate constant (λz) [Day1~Day4]
λz is a PK parameter of the single-dose stage.Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Maximum observed concentration at steady state (Cmax,ss) [Day5~Day 11]
Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured.Maximum observed concentration at steady state (Cmax,ss) is a PK parameter of the multi-dose stage.
- Minimum observed concentration at steady state (Cmin,ss) [Day5~Day 11]
Concentrations of Antimicrobial Peptide PL-18 in Plasma samples at different time points are measured. Minimum observed concentration at steady state (Cmin,ss) is a PK parameter of the multi-dose stage.
- The average concentration during a dosing interval at steady state (Cav,ss) [Day5~Day 11]
The average concentration during a dosing interval at steady state (Cav,ss) is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss) [Day5~Day 11]
AUCss is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Accumulation ratio (Rac) [Day5~Day 11]
Accumulation ratio (Rac) is a PK parameter of the multi-dose stage. Plasma PK parameters will be analyzed by non-compartmental analysis (NCA) with WinNonlin® version 8.1 or above and SAS® version 9.4 or higher.
- Characterize the effect of Antimicrobial peptide PL-18 Vaginal Suppositories on vaginal bacteria [17 days]
Changes in vaginal bacteria after single and multiple doses of Antimicrobial Peptide PL-18 Vaginal Suppositories in healthy adult female subjects assessed. Changes in vaginal bacteria will be summarized with descriptive statistics.
Eligibility Criteria
Criteria
Inclusion Criteria:
- A subject will be eligible for inclusion in this study only if all of the following criteria are met:
-
Voluntarily signed written informed consent;
-
Ability to comprehend the purpose of the study; ability to co-operate with the investigator and comply with all study requirements;
-
Adult females aged between 18 and 55 years (inclusive);
-
Body weight between 50 and 100 kg (inclusive) and body mass index (BMI) within 18~32 kg/m2 (inclusive).
-
In good health as determined by screening tests. Good health is defined as having no clinically relevant abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead ECG, and clinical laboratory tests:
-
Vital signs (measured after resting for 5 minutes seated position) within normal range, or outside the normal range and not considered clinically significant by the Investigator;
-
Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine position) in the following ranges; QTc (Fridericia algorithm recommended) ≤470 ms, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator;
-
Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. A total bilirubin outside the normal range may be acceptable if total bilirubin does not exceed 1.5 × ULN conjugated bilirubin (with the exception of a participant with documented Gilbert syndrome).
-
Self-report regular menstrual cycle (21-35 days), and planned to avoid menstruation from the first administration until 7 days after the last administration;
-
Negative human papilloma virus (HPV) test result (at screening or negative HPV test result performed in study site within 2 months prior to screening;
-
History of sexual life, including vaginal intercourse;
-
Be willing to use vaginal suppositories;
-
Currently in a mutually monogamous sexual relationship or no sexual activity;
-
Sexual abstinence from 72 hours prior to the first drug administration until 7 days after the last administration;
-
Agreement to avoid the use of any other intravaginal products (i.e., contraceptive creams, gels, foams, sponges, lubricants, irrigation solutions, etc.) from screening until 7 days after the last administration;
-
Subjects in a intercourse relationship must agree to use highly effective methods of contraception (as specified in Section 4.6.3) from informed consent obtained until 3 months after the last administration, and pregnancy test results must be negative at screening.
Exclusion Criteria:
- A subject meeting any of the following exclusion criteria will not be allowed to participate in this study:
-
Significant deep epithelial disruption by colposcopy at screening;
-
Anatomical anomalies of the genito-urinary tract and vaginal prolapse;
-
Genitourinary infections at screening or within 21 days prior to screening, including but not limited to bacterial urinary tract infection, bacterial vaginosis, trichomoniasis and vulvovaginal candidiasis;
-
Known, active sexually transmitted infection (STI) in partner, as per anamnesis;
-
Two or more confirmed trichomoniasis, gonococcal, chlamydia trachomatis or syphilis spirochete infections within 180 days prior to screening;
-
History of recurrent genital herpes or active herpes simplex virus (HSV) at screening;
-
Hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), syphilis infection, or positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), HIV antibody (HIVAb), treponema pallidum antibody (TP-Ab) at screening;
-
History of clinically severe relevant cardiovascular, hepatic, renal, pulmonary, gastrointestinal, endocrine, or neurological diseases that, in the investigator's opinion, may interfere with the aim of the study or affect the subject's safety;
-
Uncontrolled or acute illness that may complicate the study evaluation in the investigator's opinion;
-
History of hysterectomy;
-
Pelvic surgery within 90 days prior to screening;
-
Cervical cryotherapy or cervical laser treatment within 90 days prior to screening;
-
Intrauterine device insertion or removal within 90 days prior to screening;
-
Any antibiotic or antifungal therapy (intravaginal or systemic) within 30 days prior to screening;
-
Immunosuppressive therapy within 60 days prior to screening;
-
Ascertained or presumptive hypersensitivity (including allergies) to any ingredient of the investigational medicinal product (IMP); history of other significant anaphylaxis to drugs or allergic reactions in general;
-
Pregnant or lactating women, or women within 60 days of the last pregnancy;
-
Subjects who consume or are unable to abstain from products containing caffeine/xanthine within 24 hours before a visit or admission;
-
History of drug or alcohol abuse within 1year prior to screening, or a positive result of drug abuse or alcohol breath test at screening or check-in;
-
Previously dosed with an investigational drug within 3 months prior to Day 1 or still participating in another trial at the time of screening;
-
Any vaccination from the 28 days prior to administration of the first dose until 28 days after the last dose;
-
Those considered by the investigator as inappropriate to participate in the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Protelight Pharmaceuticals Australia PTY LTD
Investigators
- Study Chair: John McNeil, Professor, 90768825
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JSPL-PL-18-101